Literature DB >> 16369039

Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice.

Chahnaz Kébaïer1, Jude E Uzonna, Stephen M Beverley, Phillip Scott.   

Abstract

Leishmania major parasites lacking the GDP-mannose transporter, termed Deltalpg2 parasites, fail to induce disease in mice but persist long-term. We previously found that Deltalpg2 organisms protect BALB/c mice from virulent L. major challenge. In contrast, we report here that Deltalpg2 parasites induce protective immunity in C57BL/6 mice only when administered with CpG-containing oligodeoxynucleotides, indicating that parasite persistence alone is not sufficient to maintain protective immunity to L. major.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16369039      PMCID: PMC1346616          DOI: 10.1128/IAI.74.1.777-780.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease.

Authors:  J E Uzonna; G Wei; D Yurkowski; P Bretscher
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

2.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

Authors:  M Roman; E Martin-Orozco; J S Goodman; M D Nguyen; Y Sato; A Ronaghy; R S Kornbluth; D D Richman; D A Carson; E Raz
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

3.  Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites.

Authors:  Colby Zaph; Jude Uzonna; Stephen M Beverley; Phillip Scott
Journal:  Nat Med       Date:  2004-09-26       Impact factor: 53.440

4.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

5.  Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response.

Authors:  Jude E Uzonna; Gerald F Späth; Stephen M Beverley; Phillip Scott
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

6.  Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host.

Authors:  T Aebischer; S F Moody; E Handman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

7.  Persistence without pathology in phosphoglycan-deficient Leishmania major.

Authors:  Gerald F Späth; Lon-Fey Lye; Hiroaki Segawa; David L Sacks; Salvatore J Turco; Stephen M Beverley
Journal:  Science       Date:  2003-08-29       Impact factor: 47.728

8.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.

Authors:  P Scott; P Natovitz; R L Coffman; E Pearce; A Sher
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

9.  The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

Authors:  Y Belkaid; K F Hoffmann; S Mendez; S Kamhawi; M C Udey; T A Wynn; D L Sacks
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.

Authors:  Elizabeth G Rhee; Susana Mendez; Javeed A Shah; Chang-you Wu; Joanna R Kirman; Tara N Turon; Dylan F Davey; Heather Davis; Dennis M Klinman; Rhea N Coler; David L Sacks; Robert A Seder
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  14 in total

Review 1.  Transgenesis and neuronal ablation in parasitic nematodes: revolutionary new tools to dissect host-parasite interactions.

Authors:  J B Lok; D Artis
Journal:  Parasite Immunol       Date:  2008-04       Impact factor: 2.280

Review 2.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Human immune response to salivary proteins of wild-caught Phlebotomus papatasi.

Authors:  Rami M Mukbel; Rehab H Khasharmeh; Nawal S Hijjawi; Mohammed S Khalifeh; Ma'mon M Hatmal; Mary Ann McDowell
Journal:  Parasitol Res       Date:  2016-05-10       Impact factor: 2.289

4.  Parasite-derived arginase influences secondary anti-Leishmania immunity by regulating programmed cell death-1-mediated CD4+ T cell exhaustion.

Authors:  Zhirong Mou; Helen M Muleme; Dong Liu; Ping Jia; Ifeoma B Okwor; Shiby M Kuriakose; Stephen M Beverley; Jude E Uzonna
Journal:  J Immunol       Date:  2013-03-04       Impact factor: 5.422

5.  Sphingolipid degradation by Leishmania major is required for its resistance to acidic pH in the mammalian host.

Authors:  Wei Xu; Lijun Xin; Lynn Soong; Kai Zhang
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

Review 6.  The role of nucleotide sugar transporters in development of eukaryotes.

Authors:  Li Liu; Yu-Xin Xu; Carlos B Hirschberg
Journal:  Semin Cell Dev Biol       Date:  2010-02-06       Impact factor: 7.727

7.  Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.

Authors:  Nathan C Peters; Sylvie Bertholet; Phillip G Lawyer; Melanie Charmoy; Audrey Romano; Flavia L Ribeiro-Gomes; Lisa W Stamper; David L Sacks
Journal:  J Immunol       Date:  2012-10-08       Impact factor: 5.422

8.  Leishmania donovani lacking the Golgi GDP-Man transporter LPG2 exhibit attenuated virulence in mammalian hosts.

Authors:  Upasna Gaur; Melissa Showalter; Suzanne Hickerson; Rahul Dalvi; Salvatore J Turco; Mary E Wilson; Stephen M Beverley
Journal:  Exp Parasitol       Date:  2009-03-27       Impact factor: 2.011

9.  Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity.

Authors:  Hervé Lecoeur; Pierre A Buffet; Geneviève Milon; Thierry Lang
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

Review 10.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.